Trinity Biotech (TRIB) AI Stock Analysis

• Market Cap: $11.80M
• Dividend Yield: N/A
• Average Volume (3M): 54.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: -3.76%
• EPS Growth: 39.52%
• Country: US
• Employees: 380
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 18,632,019
• 10 Day Avg. Volume: 29,826
• 30 Day Avg. Volume: 54,103
• PEG Ratio: <0.01
• Price to Book (P/B): -306.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -96.83
• Enterprise Value/Market Cap: 60.97
• Enterprise Value/Revenue: 3.11
• Enterprise Value/Gross Profit: 35.72
• Enterprise Value/Ebitda: -10.09
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

Trinity Biotech's stock score is low due to significant financial difficulties, including declining revenues and high leverage. Technical indicators suggest a downtrend with potential overbought conditions. Although the earnings call noted some improvements, persistent challenges and a negative valuation outlook weigh heavily on the overall score.

Trinity Biotech Business Overview & Revenue Model

Company Description

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

How the Company Makes Money

Trinity Biotech generates revenue primarily through the sale of its diagnostic products. The company's key revenue streams include the sale of diagnostic tests for infectious diseases, such as HIV and hepatitis, as well as autoimmune disorders and other clinical conditions. Trinity Biotech also earns income from its point-of-care testing solutions, which are designed for use outside of traditional laboratory settings. Additionally, the company may benefit from partnerships and collaborations with other healthcare organizations, research institutions, and government bodies, which can contribute to its earnings through joint ventures, research grants, and technology licensing agreements. Trinity Biotech's focus on innovation and product development helps maintain its competitive edge and drives revenue growth in the dynamic diagnostics market.

Trinity Biotech Financial Statement Overview

Summary

Trinity Biotech is experiencing significant financial challenges with declining revenue and profitability. The company shows negative EBIT and net income margins, high leverage, and negative equity, indicating financial instability and cash flow management issues.

Income Statement

Trinity Biotech is facing significant challenges with declining revenue and profitability. The TTM (Trailing-Twelve-Months) figures show a decrease in total revenue from previous years, coupled with negative EBIT and net income margins indicating operating losses. The gross profit margin has also shrunk, reflecting rising costs or declining sales efficiency.

Balance Sheet

The balance sheet shows high leverage with a negative equity position, indicating financial instability. The debt-to-equity ratio is unfavorable, and the negative stockholders' equity suggests that liabilities exceed assets, posing a risk to the company's financial health. Return on equity is not calculable due to negative equity.

Cash Flow

The cash flow statement highlights negative operating cash flow and free cash flow, signaling cash management issues. The company's financing activities are the primary source of liquidity, which may not be sustainable long-term. The free cash flow to net income ratio is not favorable, reflecting inefficiency in cash generation relative to earnings.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
59.13M	56.83M	74.78M	92.97M	101.98M	90.44M
	Gross Profit
20.14M	19.45M	22.05M	38.08M	48.58M	38.12M
	EBIT
-13.17M	-27.05M	-10.91M	13.15M	19.11M	872.00K
	EBITDA
-10.33M	-24.10M	-16.71M	10.59M	21.52M	-19.52M
	Net Income Common Stockholders
-20.34M	-24.02M	-41.00M	875.00K	-6.01M	-4.07M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.84M	3.69M	6.58M	25.91M	27.33M	16.40M
	Total Assets
97.45M	59.44M	92.10M	118.89M	130.40M	131.07M
	Total Debt
93.72M	67.43M	58.26M	99.16M	104.34M	82.03M
	Net Debt
93.72M	63.74M	51.68M	73.25M	77.01M	65.63M
	Total Liabilities
123.79M	83.38M	94.28M	119.21M	132.62M	126.36M
	Stockholders Equity
-26.34M	-23.95M	-2.18M	-319.00K	-2.22M	4.71M
Cash Flow		Free Cash Flow
-18.73M	-14.26M	-6.90M	4.55M	13.56M	-9.88M
	Operating Cash Flow
-12.49M	-11.56M	-921.00K	13.24M	23.75M	5.47M
	Investing Cash Flow
-21.12M	24.76M	-5.98M	-8.69M	-10.20M	-15.36M
	Financing Cash Flow
30.43M	-16.04M	-12.32M	-6.02M	-2.72M	-4.00M

Trinity Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRIB, the sentiment is Negative. The current price of 0.64 is below the 20-day moving average (MA) of 0.69, below the 50-day MA of 0.68, and below the 200-day MA of 1.03, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.19 is Neutral, neither overbought nor oversold. The STOCH value of 64.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRIB.

Trinity Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	65 Neutral	$16.41M	―	-25.29%	―	26.67%	44.02%
INBS	63 Neutral	$13.20M	―	-126.34%	―	3.87%	91.76%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
BNGO	45 Neutral	$12.28M	―	-127.82%	―	-24.04%	84.11%
BIAF	42 Neutral	$7.84M	―	-290.85%	―	78.40%	22.41%
MYNZ	41 Neutral	$7.59M	―	-809.29%	―	―	―
TRIB	35 Underperform	$11.80M	―	77.20%	―	-3.76%	39.52%